Osteoporosis is a skeletal pathology characterized by compromised bone strength leading to increased risk of fracture, mainly the spine and hip fractures. Osteoporosis affects more than 200 million people worldwide and because of the skeletal fractures it causes, represents a major cause of morbidity, disability and mortality in older people. Recently, the new discoveries of osteoimmunology have clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new immunological targets for its treatment opening the way for new and effective therapies with biological drugs. Currently, there are basically two monoclonal antibodies for osteoporosis therapy: denosumab and romosozumab. Here, we focus on the modern approach to the osteoporosis management and in particular, on current and developing biologic drugs targeted to new immunological checkpoints, in the landscape of osteoimmunology.

骨质疏松症是一种骨骼病理，其特征是骨骼强度受损，导致骨折风险增加，主要是脊柱和髋部骨折。骨质疏松症影响全世界2亿多人，由于它引起的骨骼骨折，是老年人发病，残疾和死亡的主要原因。最近，骨免疫学的新发现阐明了骨质疏松症的许多致病机理，有助于确定其治疗的新免疫学靶点，从而为生物药物新的有效疗法开辟了道路。当前，基本上有两种用于骨质疏松症治疗的单克隆抗体：狄诺塞单抗和罗莫单抗。在这里，我们着重于骨质疏松症管理的现代方法，尤其是，